Hester Biosciences Q1 FY27: Profit jumps to ₹97 cr

Key takeaway from the quarter

Hester Biosciences reported a sharp rise in consolidated profitability for Q1 FY27, even as revenue declined year-on-year. Consolidated net profit increased to ₹97 crore for the quarter ended June 30, 2026, compared with ₹16.4 crore in the year-ago period. The headline jump was largely driven by an exceptional accounting gain linked to a loan amendment at its Africa subsidiary. Operationally, the company’s standalone business showed growth, led by strong performance in Poultry Healthcare. At the same time, the Animal Healthcare segment saw a steep drop in quarterly revenue due to delays in government-led livestock immunisation programmes. The results were disclosed through an exchange filing and approved by the board following audit committee recommendations. Investors also tracked the company’s corporate restructuring actions during the quarter.

Consolidated results: profit surged, revenue fell

On a consolidated basis, revenue from operations declined 8% year-on-year to ₹77.2 crore from ₹84.0 crore. Despite lower revenue, consolidated net profit rose to ₹97 crore from ₹16.4 crore, primarily due to the exceptional gain recorded during the quarter. EBITDA was broadly flat at ₹22.7 crore versus ₹22.6 crore a year earlier. The EBITDA margin improved to 29.4% from 26.9%, reflecting better margins even with softer revenue. In a separate data summary, the company reported consolidated revenue from operations at ₹77.244 crore (₹772.44 million) versus ₹84.105 crore (₹841.05 million). Consolidated net profit was also presented as ₹96.732 crore (₹967.32 million) versus ₹17.296 crore (₹172.96 million). The different presentations are consistent with the same headline numbers after unit conversion.

Exceptional gain: Gates Foundation loan amendment at HBAL

A key driver of Q1 FY27 profitability was an exceptional accounting gain of ₹85.35 crore (₹853.49 million) recorded during the quarter. The gain arose after Hester Biosciences Africa Ltd (HBAL), a wholly owned subsidiary, amended its loan agreement with the Gates Foundation. Under the revised terms, the outstanding loan principal was reduced to $1 million from $12 million. The company said all accrued interest was waived, and the remaining loan was made interest-free. It stated that the modification qualified as a substantial change under Ind AS 109. This resulted in extinguishment of the original liability and recognition of a new liability at fair value, creating the exceptional gain.

What the numbers look like without the exceptional item

The company also disclosed how profitability changes when the exceptional item is excluded. Excluding the exceptional item, profit before tax stood at ₹16.333 crore (₹163.33 million), down from ₹20.187 crore (₹201.87 million) in the corresponding quarter last year. This disclosure is important because it separates one-time accounting impact from operating performance. The quarter also showed mixed trends across geographies. While standalone operations improved, consolidated revenue declined due to lower contributions from Nepal and Africa operations as stated in the summary. This difference between standalone and consolidated trends helps explain why margins improved even as topline softened.

Standalone performance: revenue up, PAT nearly doubled

Standalone revenue from operations rose to ₹72.66 crore in Q1 FY27 from ₹63.49 crore in Q1 FY26. Standalone profit after tax (PAT) increased to ₹14.71 crore from ₹7.84 crore. The company’s standalone revenue growth was also described as approximately 14% year-on-year, based on the quarterly figures. Standalone PAT growth was described as approximately 88% year-on-year, pointing to improved profitability at the core India business. The board-approved standalone disclosure also cited total income of ₹74.343 crore (₹743.43 million) and profit after tax of ₹14.711 crore (₹147.11 million) for the June 2026 quarter. Earnings per share (EPS) for the quarter was stated at ₹17.29.

Segment trends: Poultry Healthcare strong, Animal Healthcare weak

Within operations, the Poultry Healthcare division continued to perform strongly. Segment revenue increased to ₹62.13 crore from ₹42.12 crore a year ago, a 48% year-on-year rise as highlighted in the summary. In contrast, revenue from the Animal Healthcare division fell to ₹15.11 crore from ₹41.98 crore. This segment mix shift explains why standalone performance could look strong while consolidated revenue trends remained under pressure. It also indicates how dependent quarterly results can be on tender cycles in livestock vaccination programmes. Management linked the Animal Healthcare weakness to timing rather than demand, which is relevant for interpreting the quarter’s revenue profile.

Management explanation: tender timing hit Animal Healthcare

Hester attributed the decline in its Animal Healthcare business to delays in government-led livestock immunisation programmes. It said the weakness reflected the timing of tender execution rather than any change in underlying demand for biologicals. This distinction matters because a timing-driven shortfall can reverse when tender execution resumes. The company added it remains confident about the long-term growth prospects of preventive animal healthcare. It also said it will continue strengthening its biologicals portfolio across both Poultry and Animal Healthcare during FY27. These statements frame the quarter as one with a strong poultry-led base but uneven tender-led livestock revenue.

Corporate action: exit from Texas Lifesciences

The quarter also featured a strategic simplification step. Hester divested its entire remaining 11% stake in Texas Lifesciences Private Limited. The divestment value was stated at ₹2.3 crore, and the transaction date was July 8, 2026. The move completes the company’s exit from the associate and reduces complexity in the group structure. For investors, such clean-ups can improve clarity in consolidated reporting, even though the immediate financial impact is small relative to quarterly profits. The disclosure also aligns with the company’s broader messaging around restructuring and portfolio focus.

Market reaction and near-term investor focus

Shares of Hester Biosciences rose as much as 6% on Thursday, July 30, following the results announcement. The market response reflected the scale of the headline profit increase and the visibility of the exceptional item. But investors also focused on the 8% revenue decline and the sharp drop in Animal Healthcare revenue, which management linked to government programme timing. EBITDA being largely unchanged while margins improved suggested cost control and mix benefits. The loan amendment outcome at HBAL was a major one-off factor, and the company’s disclosure under Ind AS 109 provided the accounting context. The segment split between poultry and animal healthcare became a key datapoint for tracking quarterly volatility.

Earnings call schedule and disclosure process

Hester announced an earnings conference call for July 30, 2026, to discuss Q1 FY27 results. The call was scheduled for Thursday, July 30, 2026 at 2:00 p.m. IST. It was to be coordinated by ICICI Securities and attended by CEO Rajiv Gandhi, Executive Director Priya Gandhi, and CFO Ashish Desai. Separately, the company said its board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, following audit committee recommendations. It also said it would publish an extract of the results in newspapers in line with SEBI disclosure requirements.

Key numbers at a glance

Conclusion

Hester Biosciences’ Q1 FY27 results combined a one-time accounting gain with a strong standalone performance in Poultry Healthcare and a tender-timing driven decline in Animal Healthcare. The exceptional gain from the Gates Foundation loan amendment at HBAL largely explains the jump in consolidated net profit to ₹97 crore. Investors will likely track whether Animal Healthcare revenues normalise as government immunisation tenders progress, and how the company sustains margins with shifting segment mix. The scheduled earnings call on July 30, 2026 is the next formal update where management is expected to address operating trends and the quarter’s accounting impacts.